Evidence map›Paper›PMID 32118206›Full record

ArticleNeuro-oncology advances

Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.

Matthew S Ji, Blaine S C Eldred, Regina Liu, Sean T Pianka, Donna Molaie, Bryan Kevan, Stephanie Pan, Thomas J Lai, Nhung T Nguyen, Frances E Chow and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Matthew S JiUCLA Department of Neurology, Los Angeles, California.
Blaine S C EldredUCLA Department of Neurology, Los Angeles, California.
Regina LiuUCLA Department of Neurology, Los Angeles, California.
Sean T PiankaUCLA Department of Neurology, Los Angeles, California.
Donna MolaieUCLA Department of Neurology, Los Angeles, California.
Bryan KevanUCLA Department of Biostatistics, Los Angeles, California.
Stephanie PanUCLA Department of Neurology, Los Angeles, California.
Thomas J LaiUCLA Department of Neurology, Los Angeles, California.
Nhung T NguyenUCLA Department of Neurology, Los Angeles, California.
Frances E ChowUCLA Department of Neurology, Los Angeles, California.
William H YongUCLA Department of Neurology, Los Angeles, California.
Christopher D CoxUCLA Department of Neurology, Los Angeles, California.
Devin N ReehUCLA Department of Mathematics, Los Angeles, California.
Tie LiUCLA Department of Neurology, Los Angeles, California.
Linda M LiauUCLA Department of Neurosurgery, Los Angeles, California.
Phioanh L NghiemphuUCLA Department of Neurology, Los Angeles, California.
Timothy F CloughesyUCLA Department of Neurology, Los Angeles, California.
Gang LiUCLA Department of Biostatistics, Los Angeles, California.
Albert LaiUCLA Department of Neurology, Los Angeles, California.
UCLA Health · USUniversity of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Investigation of tumor suppressive miR-148a in IDH mutant gliomasR01CA179071 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAI, ALBERT · 2014 to 2018
$1.6M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA179071
6 · The paper itself

Abstract

backgroundTargeted next-generation sequencing (NGS) is frequently obtained at the University of California, Los Angeles (UCLA) for clinical characterization of CNS tumors. In this study, we describe the diagnostic reliability of the Foundation Medicine (FM) targeted NGS platform and its ability to explore and identify tumor characteristics of prognostic significance in gliomas.

methodsNeuro-oncology patients seen at UCLA who have received FM testing between August 2012 and March 2019 were included in this study, and all mutations from FM test reports were recorded. Initial tumor diagnoses and diagnostic markers found via standard clinical methods were obtained from pathology reports. With overall and progression-free survival data, elastic net regularized Cox regression and Cox proportional hazards models were used to determine whether any mutations of unknown significance detected by FM could predict patient outcome in glioblastoma (GBM).

resultsSix hundred and three samples tested by FM from 565 distinct patients were identified. Concordance of diagnostic markers was high between standard clinical testing methods and FM. Oligodendroglial markers detected via FM were highly correlated with 1p19q codeletion in

conclusionsIn our large cohort, we found that targeted NGS can both reliably and efficiently detect important diagnostic markers in CNS tumors.

Indexed as

CNS tumorsgenomic profilingglioblastomagliomatargeted next-generation sequencing

Identifiers

PMID32118206
PMCPMC7034640
OpenAlexW3004149570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.